Home › Compare › VBLT vs RYLD

VBLT vs RYLD: Dividend Comparison 2026

VBLT yields 1282.05% · RYLD yields 12.14%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 VBLT wins by $169777724.37M in total portfolio value
10 years
VBLT
VBLT
● Live price
1282.05%
Share price
$0.16
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$169777724.42M
Annual income
$147,192,786,254,209.56
Full VBLT calculator →
RYLD
RYLD
● Live price
12.14%
Share price
$14.95
Annual div
$1.81
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$44.5K
Annual income
$2,587.35
Full RYLD calculator →

Portfolio growth — VBLT vs RYLD

📍 VBLT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodVBLTRYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, VBLT + RYLD cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
VBLT pays
RYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

VBLT
Annual income on $10K today (after 15% tax)
$108,974.36/yr
After 10yr DRIP, annual income (after tax)
$125,113,868,316,078.12/yr
RYLD
Annual income on $10K today (after 15% tax)
$1,031.60/yr
After 10yr DRIP, annual income (after tax)
$2,199.25/yr
At 15% tax rate, VBLT beats the other by $125,113,868,313,878.88/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of VBLT + RYLD for your $10,000?

VBLT: 50%RYLD: 50%
100% RYLD50/50100% VBLT
Portfolio after 10yr
$84888862.23M
Annual income
$73,596,393,128,398.45/yr
Blended yield
86.70%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on VBLT right now

VBLT
Analyst Ratings
6
Buy
2
Hold
Consensus: Buy
Price Target
$5.00
+3105.1% upside vs current
Range: $5.00 — $5.00
Altman Z
-19.9
Piotroski
0/9
RYLD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

VBLT buys
0
RYLD buys
0
No recent congressional trades found for VBLT or RYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricVBLTRYLD
Forward yield1282.05% ✓12.14%
Annual dividend / share$2.00 ✓$1.81
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$169777724.42M ✓$44.5K
Annual income after 10y$147,192,786,254,209.56 ✓$2,587.35
Total dividends collected$168105692.30M ✓$18.8K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: VBLT vs RYLD ($10,000, DRIP)

YearVBLT PortfolioVBLT Income/yrRYLD PortfolioRYLD Income/yrGap
1← crossover$138,905$128,205.13$11,914$1,213.65+$127.0K → VBLT
2$1,812,960$1,664,331.75$14,099$1,351.30+$1.80M → VBLT
3$22,241,274$20,301,406.25$16,580$1,494.55+$22.22M → VBLT
4$256,561,041$232,762,878.32$19,384$1,642.61+$256.54M → VBLT
5$2,783,868,903$2,509,348,588.72$22,535$1,794.70+$2783.85M → VBLT
6$28,425,663,485$25,446,923,758.80$26,063$1,950.00+$28425.64M → VBLT
7$273,251,611,466$242,836,151,537.34$29,995$2,107.69+$273251.58M → VBLT
8$2,474,012,179,526$2,181,632,955,256.89$34,361$2,266.99+$2474012.15M → VBLT
9$21,107,418,843,486$18,460,225,811,393.34$39,194$2,427.12+$21107418.80M → VBLT
10$169,777,724,416,739$147,192,786,254,209.56$44,525$2,587.35+$169777724.37M → VBLT

VBLT vs RYLD: Complete Analysis 2026

VBLT — Stock

Vascular Biogenics Ltd., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. Its programs are based on its vascular targeting system, a gene-based technology targeting newly formed blood vessels; and monocyte targeting technology, an antibody-based technology that enables specifically inhibit monocyte migration for immune-inflammatory applications. The company's lead product candidate is VB-111, a gene-based biologic that is in Phase III clinical trials for the recurrent platinum-resistant ovarian cancer; and Phase II clinical trials treatment of recurrent glioblastoma and colorectal cancer, as well as has completed Phase II clinical trial for the treatment of thyroid cancer. It is also developing VB-601 for various inflammatory indications, and VB-611 for various solid tumors. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modi'in, Israel.

Full VBLT Calculator →

RYLD — ETF

The Global X Russell 2000 Covered Call ETF (RYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Russell 2000 BuyWrite Index.

Full RYLD Calculator →
📬

Get this VBLT vs RYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

VBLT vs SCHDVBLT vs JEPIVBLT vs OVBLT vs KOVBLT vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.